|
gptkbp:instanceOf
|
gptkb:drug
gptkb:anticoagulant
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
B01AC04
|
|
gptkbp:bioavailability
|
50%
|
|
gptkbp:brand
|
gptkb:Clopilet
gptkb:Plavix
Iscover
|
|
gptkbp:CASNumber
|
113665-84-2
|
|
gptkbp:chemicalFormula
|
C16H16ClNO2S
|
|
gptkbp:contraindication
|
severe liver impairment
active bleeding
|
|
gptkbp:developedBy
|
gptkb:France
|
|
gptkbp:discoveredBy
|
gptkb:Sanofi
|
|
gptkbp:drugClass
|
thienopyridine
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericAvailable
|
yes
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
clopidogrel
|
|
gptkbp:interactsWith
|
gptkb:warfarin
gptkb:omeprazole
gptkb:aspirin
statins
esomeprazole
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
P2Y12 receptor antagonist
|
|
gptkbp:metabolism
|
liver
active thiol metabolite
|
|
gptkbp:molecularWeight
|
321.82 g/mol
|
|
gptkbp:patentExpired
|
2012
|
|
gptkbp:pregnancyCategory
|
B (US)
B1 (Australia)
|
|
gptkbp:proteinBinding
|
98%
|
|
gptkbp:riskFactor
|
gastrointestinal bleeding
neutropenia
thrombotic thrombocytopenic purpura
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
bleeding
rash
bruising
|
|
gptkbp:usedFor
|
prevention of stroke
prevention of myocardial infarction
prevention of peripheral arterial disease
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
5
|